May 20th 2024
Developers voluntarily request withdrawal of accelerated approval status for infigratinib as a treatment for FGFR2-positive cholangiocarcinoma.
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
SIRFLOX Regimen Delays Liver Progression in Metastatic Colorectal Cancer
February 25th 2016The addition of selective internal radiation therapy with yttrium-90 resin microspheres to standard FOLFOX chemotherapy did not improve progression-free survival in patients with metastatic colorectal cancer, but it did significantly delay disease progression in the liver.
Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer
January 16th 2016Here, we review the studies that have explored different treatment regimens, therapeutic sequencing, and biologic inclusions for the treatment of these patients, with neoadjuvant intent. We also describe how we have established our own treatment paradigm for the management of potentially curable metastatic colorectal cancer.
Modern Immunotherapy for the Treatment of Advanced Gastrointestinal Cancers
January 15th 2016Although immunotherapy is not yet approved for the treatment of gastrointestinal cancers, it is already clear that many gastrointestinal cancers can be sensitive to it. We will review recent clinical trial results demonstrating this, and offer our perspective on the role that immunotherapy might play in the treatment of advanced gastrointestinal malignancies in the years ahead.
Race, Geography Associated With Resection Rates in Pancreatic Cancer
November 24th 2015A retrospective cohort study showed that socioeconomic variables including race, marital status, insurance status, and geography are associated with rates of resection for early-stage pancreatic cancer. Most of these factors, however, were not associated with survival following resection.
Dietary Factors Linked to Changes in Gastric Cancer Risk
November 23rd 2015A meta-analysis found that a number of dietary factors play a role in the risk of developing gastric cancer, with protective effects seen with fruit and certain vegetables and increased risk seen with high-salt foods and certain forms of alcohol.
Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma
November 16th 2015This article reviews the current treatment paradigms for metastatic disease, focusing on ways to ameliorate symptoms and lengthen survival. We then summarize recent advances in our understanding of the molecular and cellular aspects of pancreatic cancer.
Systemic Therapy of Pancreatic Cancer: Better Science, Faster Progress
November 15th 2015The ultimate benefit to patients will come from a demonstration of clinically worthwhile benefits of new drugs that have been tested in well-designed and adequately powered clinical trials performed in an expedited fashion.
FDA Approves New Treatment for Metastatic Pancreatic Cancer
October 23rd 2015The FDA has approved the combination of irinotecan liposome injection plus 5-fluorouracil and leucovorin for the treatment of metastatic pancreatic cancer in patients who previously progressed on gemcitabine-based chemotherapy.